Hematologics, Inc   Report issue

For profit Phase 2
Founded: Seattle WA United States (1995)

Organization Overview

First Clinical Trial
2019
NCT04050280
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Hematologics, Inc

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 4